Cidara Therapeutics, Inc. CDTX
Jan 8, 2026, 9:30 AM EST
52-week range unavailable
- YTD
- +0.22%
- 1 year
- +725.74%
- Market cap
- 5.61B
- YTD return
- +0.22%
- 1-year return
- +725.74%
- Volume
- 2.69M
- Open
- 221.38
- Previous close
- 221.38
- Day's range
- 221.38 – 221.38
Key statistics
- Enterprise value
- 5.32B
- PEG ratio
- -1.58
- Price / sales
- 0.00
- Price / book
- 8.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -23.59%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2025 | Sep 30, 2025 | -1.34 | -3.10 | -1.76 | -131.34% |
| Aug 7, 2025 | Jun 30, 2025 | -1.87 | -1.65 | +0.22 | +11.76% |
| May 8, 2025 | Mar 31, 2025 | -5.45 | -1.66 | +3.79 | +69.54% |
| Mar 6, 2025 | Dec 31, 2024 | -5.28 | -5.38 | -0.10 | -1.89% |
| Nov 7, 2024 | Sep 30, 2024 | -5.22 | -2.38 | +2.84 | +54.41% |
| Aug 13, 2024 | Jun 30, 2024 | -3.94 | -19.99 | -16.05 | -407.36% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2025 | Guggenheim | down | Buy | Neutral |
| Nov 14, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 14, 2025 | Needham | down | Buy | Hold |
| Nov 7, 2025 | RBC Capital | main | Outperform | Outperform |
| Nov 7, 2025 | Needham | main | Buy | Buy |
| Oct 21, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 38
- Website
- msd.platform-apps.io
News
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight 
12 Health Care Stocks Moving In Friday's Intraday Session 
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher 
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday 
Nasdaq Dips Over 300 Points; Applied Materials Posts Upbeat Q4 Earnings 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket 
Earnings Scheduled For November 6, 2025 
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday 
Earnings Scheduled For August 7, 2025
Your note
Sign in to keep a note on CDTX — it syncs with the Stock Master app.